Table 1 The characteristics of HCC patients in training cohort and validation cohort.
Characteristic | Training cohort (n = 247) | Validation cohort (n = 124) | P value |
|---|---|---|---|
Age, median (IQR) | 61 (51, 69) | 61 (52, 68) | 0.762 |
BMI, meidan (IQR) | 24.45 (22.15, 28.99) | 24.3 (21.35, 28.12) | 0.375 |
Gender, n (%) | Â | Â | 0.473 |
Female | 77 (31.2%) | 44 (35.5%) | Â |
Male | 170 (68.8%) | 80 (64.5%) | Â |
Family cancer history, n (%) | Â | Â | 0.639 |
Yes | 75 (33.9%) | 37 (37.4%) | Â |
No | 146 (66.1%) | 62 (62.6%) | Â |
Race, n (%) | Â | Â | 0.378 |
American indian or alaska native | 1 (0.4%) | 1 (0.8%) | Â |
Asian | 112 (46.5%) | 46 (38.4%) | Â |
Black or african american | 10 (4.1%) | 7 (5.8%) | Â |
White | 118 (49.0%) | 66 (55.0%) | Â |
Alcohol consumption, n (%) | Â | Â | 0.170 |
Yes | 84 (35.9%) | 33 (28.0%) | Â |
No | 150 (64.1%) | 85 (72.0%) | Â |
Hepatitis B, n (%) | Â | Â | 0.405 |
Yes | 73 (31.2%) | 31 (26.3%) | Â |
No | 161 (68.8%) | 87 (73.7%) | Â |
Hepatitis C, n (%) | Â | Â | 0.144 |
Yes | 32 (13.7%) | 24 (20.3%) | Â |
No | 202 (86.3%) | 94 (79.7%) | Â |
T stage, n (%) | Â | Â | 0.767 |
T1 | 122 (49.6%) | 59 (48.0%) | Â |
T2 | 59 (24.0%) | 35 (28.5%) | Â |
T3 | 54 (22.0%) | 26 (21.1%) | Â |
T4 | 10 (4.1%) | 3 (2.4%) | Â |
TX | 1 (0.3%) | 0 (0%) | Â |
N stage, n (%) | Â | Â | 0.736 |
N0 | 167 (67.9%) | 85 (68.6%) | Â |
N1 | 2 (0.8%) | 2 (1.6%) | Â |
NX | 77 (31.3%) | 37 (29.8%) | Â |
M stage, n (%) | Â | Â | 1.000 |
M0 | 177 (71.7%) | 89 (71.8%) | Â |
M1 | 3 (1.2%) | 1 (0.8%) | Â |
MX | 67 (27.1%) | 34 (27.4%) | Â |
Pathologic stage, n (%) | Â | Â | 0.766 |
Stage I | 118 (50.9%) | 53 (46.1%) | Â |
Stage II | 55 (23.7%) | 31 (27.0%) | Â |
Stage III | 55 (23.7%) | 30 (26.1%) | Â |
Stage IV | 4 (1.7%) | 1 (0.8%) | Â |
Neoplasm histologic grade, n (%) | Â | Â | 0.481 |
G1 | 33 (13.6%) | 22 (17.9%) | Â |
G2 | 118 (48.6%) | 59 (48.0%) | Â |
G3 | 82 (33.7%) | 40 (32.5%) | Â |
G4 | 10 (4.1%) | 2 (1.6%) | Â |
Child–pugh classification grade, n (%) |  |  | 0.172 |
A | 147 (92.5%) | 70 (87.5%) | Â |
B | 12 (7.5%) | 9 (11.3%) | Â |
C | 0 (0%) | 1 (1.2%) | Â |
Microvascular invasion, n (%) | Â | Â | 1.000 |
Yes | 72 (34.4%) | 37 (34.9%) | Â |
None | 137 (65.6%) | 69 (65.1%) | Â |
